ST Germain D J Co. Inc. boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 5.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 82,348 shares of the medical research company’s stock after buying an additional 4,042 shares during the period. Amgen makes up about 1.0% of ST Germain D J Co. Inc.’s holdings, making the stock its 28th largest holding. ST Germain D J Co. Inc.’s holdings in Amgen were worth $21,463,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC grew its stake in Amgen by 54.7% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 504,280 shares of the medical research company’s stock worth $131,436,000 after buying an additional 178,304 shares in the last quarter. ORG Partners LLC lifted its holdings in shares of Amgen by 0.5% during the 4th quarter. ORG Partners LLC now owns 8,975 shares of the medical research company’s stock worth $2,345,000 after acquiring an additional 41 shares during the last quarter. Watts Gwilliam & Co. LLC grew its position in Amgen by 0.7% in the fourth quarter. Watts Gwilliam & Co. LLC now owns 17,651 shares of the medical research company’s stock worth $4,626,000 after acquiring an additional 128 shares in the last quarter. Legacy Private Trust Co. increased its stake in Amgen by 11.3% in the fourth quarter. Legacy Private Trust Co. now owns 7,716 shares of the medical research company’s stock valued at $2,011,000 after acquiring an additional 784 shares during the last quarter. Finally, InvesTrust bought a new position in Amgen in the fourth quarter valued at $267,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.
Amgen Stock Performance
Amgen stock traded down $2.31 during trading on Friday, reaching $261.90. The company had a trading volume of 671,499 shares, compared to its average volume of 2,703,621. The firm has a market capitalization of $140.78 billion, a price-to-earnings ratio of 33.53, a price-to-earnings-growth ratio of 2.91 and a beta of 0.56. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The firm’s 50-day simple moving average is $280.24 and its 200 day simple moving average is $309.15. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85.
Amgen Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a dividend of $2.38 per share. This is a positive change from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.63%. Amgen’s dividend payout ratio (DPR) is presently 121.90%.
Analyst Upgrades and Downgrades
Several equities research analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft dropped their price target on Amgen from $305.00 to $285.00 in a research note on Wednesday, November 27th. Wolfe Research started coverage on Amgen in a research report on Friday, November 15th. They issued a “peer perform” rating for the company. Truist Financial reduced their price target on shares of Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a research report on Wednesday. Cantor Fitzgerald restated an “overweight” rating and issued a $405.00 price objective on shares of Amgen in a report on Tuesday, October 22nd. Finally, Royal Bank of Canada cut their price objective on shares of Amgen from $360.00 to $330.00 and set an “outperform” rating for the company in a research note on Wednesday, November 27th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Amgen currently has an average rating of “Hold” and an average price target of $314.91.
Check Out Our Latest Stock Report on Amgen
Amgen Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Read More
- Five stocks we like better than Amgen
- Top Biotech Stocks: Exploring Innovation Opportunities
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.